Bristol-Myers Squibb partners with Anthropic to launch AI agent development

The biopharmaceutical sector is transitioning from basic chat assistants to agentic AI. Bristol Myers Squibb (BMS) has announced a strategic partnership with Anthropic, deploying Claude Enterprise as its global intelligent platform. This advanced AI system is now accessible to over 30,000 employees worldwide.

From Conversation to Agent: AI in Pharmaceutical R&D

This partnership represents a major shift in BMS's AI strategy. Rather than relying on simple conversational tools, BMS is integrating Claude's agentic capabilities directly into core systems and daily workflows. The initiative targets three key areas:

Accelerating Software and Algorithm Development: By using Anthropic's Claude Code, BMS's engineering and data science teams can significantly speed up software development. This approach standardizes cross-business collaboration and breaks down industry-wide data silos, allowing for the reconstruction and use of data and expert knowledge previously locked in isolated systems.

Embedding Intelligent Agents in Core Value Chains: BMS is integrating Claude as an agentic layer into high-frequency workflows:

Drug Discovery: Leveraging AI's reasoning capabilities to analyze decades of scientific, molecular, and clinical data, helping researchers identify and optimize targets in oncology and hematology.

Clinical Development: AI automates tedious documentation, from drafting clinical study reports to preparing patient safety narratives. This aims to significantly shorten the timeline from data lock to filing.

Production and Quality Control: Full automation is achieved for root cause investigations and corrective and preventive action (CAPA) documentation. This optimizes batch release decisions, speeding up production while maintaining compliance.

Activating Institutional Knowledge Bases: Secure integration with internal scientific, clinical, and commercial databases allows Claude to retrieve cross-departmental expertise in real time. This ensures employees have accurate contextual support for decision-making.

Industry Context: McKinsey's Efficiency Leap

McKinsey predicts that Agentic AI could reshape biopharmaceutical operations within five years, potentially boosting clinical R&D efficiency by 35% to 45%. This forecast is materializing as AI optimizes clinical trial design, accelerates subject matching, and reduces attrition rates. By analyzing historical trial data, real-world evidence, and patient records, AI helps pharmaceutical companies gain a competitive edge in drug development.

Life Sciences Competition: Anthropic vs. OpenAI

This collaboration strengthens Anthropic's position in life sciences, where competition is fierce. OpenAI has already partnered with Moderna and Novo Nordisk, focusing on drug discovery and process automation. In response, Anthropic aims to embed its intelligent layer into global pharmaceutical infrastructure, leveraging Claude's reasoning capabilities and commitment to enterprise data security.

For Bristol Myers Squibb, this partnership is more than a tech upgrade; it is a critical step toward becoming an AI-driven pharmaceutical company. By transforming AI from a passive tool into an autonomous agent, BMS addresses long-standing industry challenges like lengthy development cycles and high costs, accelerating the delivery of innovative drugs to patients globally.